Coherus Biosciences Embarks on Strategic Financial Restructuring
Company Announcements

Coherus Biosciences Embarks on Strategic Financial Restructuring

Coherus Biosciences (CHRS) has shared an announcement.

Coherus BioSciences, Inc. secured a $38.7 million senior secured term loan on May 8, 2024, to repay previous debts, with terms including an 8.00% interest rate plus SOFR and a sliding scale prepayment fee. The loan, maturing in 2029, is backed by the company’s assets and includes a cash maintenance covenant. Additionally, the company sold revenue rights for two products to Coduet Royalty Holdings, LLC for $37.5 million, with the option to repurchase these rights, signifying strategic financial restructuring to strengthen its financial position.

For detailed information about CHRS stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyBiotech Alert: Searches spiking for these stocks today
TipRanks Auto-Generated NewsdeskCoherus Biosciences Manages UDENYCA Supply Interruption and Cost Reductions
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App